Melissa Busch, LabPulse.com assistant editor; Emily Hayes, editor in chiefHPVHPV, Pap cotesting best for cervical cancer detection in Quest studyCotesting involves Pap and HPV screening using the same specimen. A new study of women 30 years or older by researchers at Quest Diagnostics and the University of Pittsburgh Medical Center found that cotesting outperformed HPV or Pap testing alone for detecting precancer or cancer. In the retrospective study, the researchers evaluated deidentified results for tests conducted between 2010 and 2018 by Quest in 13.6 million women; 8,059 had precancers and 1,259 were subsequently diagnosed with cervical cancer.July 8, 2020Page 1 of 1Top StoriesPoint-of-Care TestingScout secures CARB-X grant to advance diagnostic test developmentScout, formerly Uh Oh Labs, will advance its point-of-care (POC) diagnostic test for sexually transmitted infections (STIs) with a new $1 million accelerator grant.Alzheimer'sQuest adds new biomarker test to Alzheimer's portfolioLawsuitBio-Techne files patent infringement suit against Molecular InstrumentsNeurodegenerative DiseaseTarget ALS launches new data portal for researchSponsor ContentVisit our Molecular Diagnostics Community
